Ostatnia aktualizacja :
26/03/2024
Znieczulenie miejscowe   Lidocaine hydrochloride  
Injekcje
Maści Roztwór do płukania gardła
Trwałość roztworów Trwałość w mieszaninie Czynnik wpływający na trwałość Zgodność Sposób podania Bibliografia Pdf
   Struktura chemiczna  

Nazwa handlowa   Nazwa handlowa     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Jetokaine Turcja
Lidocard Finlandia
Lidocorit Austria
Lidosen Włochy
Lidrian Włochy
Linisol Belgia
Locaine Afryka Południowa
Minijet lignocaine Wielka Brytania
Pisacaina Ekwador, Meksyk
Plidocain Polska
Rapidocain Szwajcaria
Remicaine Afryka Południowa
Remicard Afryka Południowa
Xilina Rumunia
Xylanest Austria
Xylesine Szwajcaria
Xylestesin Brazylia
Xylocain Austria, Dania, Finlandia, Kanada, Norwegia, Polska, Szwajcaria, Szwecja
Xylocaina Brazylia, Włochy
Xylocaine Australia, Belgia, Francja , Grecja, Holandia, Kanada, Luksemburg, Malezja, Maroko, Stany Zjednoczone Ameryki, Słowenia
Xylocard Arabia Saudyjska, Australia, Austria, Belgia, Egipt, Francja , Kanada, Portugalia, Szwecja
Xylocitin Niemcy
Xyloneural Austria, Szwajcaria
Bibliografia   Injekcje   Bibliografia : Lidocaine hydrochloride  
Typ Publikacja
59 Czasopismo Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
62 Czasopismo Pugh CB, Pabis DJ, Rodriguez C.
Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 123-125.
92 Czasopismo Lee CY, Mauro VF, Alexander KS.
Visual and spectrophotometric determination of compatibility of alteplase and streptokinase with other injectable drugs.
Am J Hosp Pharm 1990 ; 47: 606-608.
187 Czasopismo Olsen KM, Gurley BJ, Davis GA, Christensen R, Monaghan MS.
Stability of flumazenil with selected drugs in 5% dextrose injection.
Am J Hosp Pharm 1993 ; 50: 1907-1912.
198 Czasopismo Gayed AA, Kheshary PR, Hinkle RL.
Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 516-520.
210 Czasopismo Stewart JT, Warren FW, King AD.
Stability of ranitidine hydrochloride and seven medications.
Am J Hosp Pharm 1994 ; 51: 1802-1807.
214 Czasopismo Galante LJ, Stewart JT, Warren FW, Edgar JW, Huff AJ.
Stability of ranitidine hydrochloride with eight medications in intravenous admixtures.
Am J Hosp Pharm 1990 ; 47: 1606-1610.
240 Czasopismo Lam XM, Ward CA, de C du M?e CPR.
Stability and activity of alteplase with injectable drugs commonly used in cardiac therapy.
Am J Health-Syst Pharm 1995 ; 52: 1904-1909.
242 Czasopismo Campbell S, Nolan PE, Bliss M, Wood R, Mayersohn M.
Stability of amiodarone hydrochloride in admixtures with other injectable drugs.
Am J Hosp Pharm 1986 ; 43: 917-921.
278 Czasopismo Hagan RL, Carr-Lopez S, Strickland JS.
Stability of nafcillin sodium in the presence of lidocaine hydrochloride.
Am J Health-Syst Pharm 1995 ; 52: 521-523.
279 Czasopismo Bailey LC, Cappel KM, Orosz ST.
Stability of ceftriaxone sodium in injectable solutions stored frozen in syringes.
Am J Hosp Pharm 1994 ; 51: 2159-2161.
288 Czasopismo Cervenka P, Dejong DJ, Butler BL, Monzingo MD.
Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration.
Hosp Pharm 1992 ; 27: 957-958,961-962.
299 Czasopismo Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300 Czasopismo Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
315 Czasopismo Bahal SM, Lee TJ, McGinnes M, Dobler GL.
Visual compatibility of warfarin sodium injection with selected medications and solutions.
Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
317 Czasopismo Kershaw BP, Monnier HL, Mason JH.
Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration.
Am J Hosp Pharm 1993 ; 50: 1360-1362.
319 Czasopismo Hadzija BW, Lubarsky DA.
Compatibility of etomidate, thiopental sodium, and propofol injections with drugs commonly administered during induction of anesthesia.
Am J Health-Syst Pharm 1995 ; 52: 997-999.
386 Czasopismo Colucci RD, Cobuzzi LE, Halpern NA.
Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1357-1358.
397 Czasopismo Fong PA, Ward J.
Visual compatibility of intravenous famotidine with selected drugs.
Am J Hosp Pharm 1989 ; 46: 125-126.
398 Czasopismo Jay GT, Fanikos J, Souney PF.
Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1556-1557.
403 Czasopismo Outman WR, Monolakis J.
Visual compatibility of haloperidol lactate with 0.9% sodium chloride injection or injectable critical-care drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 1539-1541.
499 Czasopismo Rockwell K, Burch K.
Intramuscular antibiotic preparation and administration using a 1% lidocaine diluent: policies for the pediatric patient.
Hosp Pharm 1991 ; 26: 634-635.
524 Czasopismo Farquhar Zanetti LA.
Visual compatibility of diltiazem with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1992 ; 49: 1911.
612 Czasopismo Frable RA, Klink PR, Engel GL, Mundell EE.
Stability of cefamandole nafate injection with parenteral solutions and additives.
Am J Hosp Pharm 1982 ; 39: 622-627.
619 Czasopismo Kirschenbaum HL, Aronoff W, Perentesis GP, Plitz GW, Cutie AJ.
Stability and compatibility of lidocaine hydrochloride with selected large-volume parenterals and drugs additives.
Am J Hosp Pharm 1982 ; 39: 1013-1015.
626 Czasopismo Bornstein M, Lo AY, Thomas PN, Wilham WL.
Moxalactam disodium compatibility with intramuscular and intravenous diluents.
Am J Hosp Pharm 1982 ; 39: 1495-1498.
660 Czasopismo Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232.
705 Czasopismo Lee YC, Malick W, Amann AH, Baaske DM, Shah JJ, Wagenknecht DM, Carter JE.
Bretylium tosylate admixture compatibility. II : Dopamine, lidocaine, procainamide, and nitroglycerin.
Am J Hosp Pharm 1981 ; 38: 183-187.
706 Czasopismo Cutie MR.
Compatibility of verapamil hydrochloride with other additives.
Am J Hosp Pharm 1981 ; 38: 231.
730 Czasopismo Allen LV, Saul Levinson R, Phisutsinthop D.
Compatibility of various admixtures with secondary additives at Y-injection site of intravenous administration sets.
Am J Hosp Pharm 1977 ; 34: 939-943.
738 Czasopismo Gardella LA, Kesler H, Amann A, Carter JE.
Intropin (dopamine hydrochloride) intravenous admixture compatibility. Part 3: Stability with miscellaneous additives.
Am J Hosp Pharm 1978 ; 35: 581-584.
794 Czasopismo Lilley EMM, Isert PR, Carasso ML, Kennedy RA.
The effect of the addition of lignocaine on propofol emulsion stability.
Anaesthesia 1996 ; 51: 815-818.
921 Czasopismo Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
925 Czasopismo Dupuis LL, Trope A, Giesbrecht E, Wong B.
Compatibility and stability of propafenone hydrochloride with five critical-care medications.
Can J Hosp Pharm 1998 ; 51: 55-57.
1036 Czasopismo Hasegawa GR, Eder JF.
Visual compatibility of amiodarone hydrochloride injection with other injectable drugs.
Am J Hosp Pharm 1984 ; 41: 1379-1380.
1041 Czasopismo Hasegawa GR, Eder JF.
Visual compatibility of dobutamine hydrochloride with other injectable drugs.
Am J Hosp Pharm 1984 ; 41: 949-951.
1049 Czasopismo Klamerus KJ, Ueda CT, Newton DW.
Stability of nitroglycerin in intravenous admixtures.
Am J Hosp Pharm 1984 ; 41: 303-305.
1058 Czasopismo Kirschenbaum HL, Aronoff W, Piltz GW, Perentesis GP, Cutie AJ.
Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives.
Am J Hosp Pharm 1983 ; 40: 1690-1691.
1072 Czasopismo Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA.
Compatibility of levofloxacin with 34 medications during simulated Y-site administration.
Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1126 Czasopismo Lackner TE, Baldus D, Butler CD, Amyx C, Kessler G.
Lidocaine stability in cardioplegic solution stored in glass bottles and polyvinyl chloride bags.
Am J Hosp Pharm 1983 ; 40: 97-101.
1193 Czasopismo Perentesis GP, Plitz GW, Kirschenbaum HL, Navalakha P, Aronoff W, Cutie AJ.
Stability and visual compatibility of bretylium tosylate with selected large-volume parenterals and additives.
Am J Hosp Pharm 1983 ; 40: 1010-1012.
1201 Czasopismo Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG.
Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures.
Am J Hosp Pharm 1981 ; 38: 1919-1922.
1202 Czasopismo Smith FM, Nuessle NO.
Stability of lidocaine hydrochloride in 5% dextrose injection in plastic bags.
Am J Hosp Pharm 1981 ; 38: 1745-1747.
1232 Czasopismo Beatson C, Taylor A.
A physical compatibility study of furosemide & flucloxacillin injections.
Br J Pharm Pract 1987 ; 9: 223-226, 236.
1315 Czasopismo Halpern NA, Colucci RD, Alicea M, Greenstein R.
Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1331 Czasopismo Das Gupta V, Steward KR.
Chemical stabilities of lignocaine hydrochloride and phenylephrine hydrochloride in aqueous solution.
J Clin Hosp Pharm 1986 ; 11 : 449-452.
1338 Czasopismo Baptista RJ, Dumas GJ, Bistrian BR, Condella F, Blackburn GL.
Compatibility of total nutrient admixtures and secondary cardiovascular medications.
Am J Hosp Pharm 1985 ; 42: 777-778.
1420 Czasopismo Bergquist PA, Hunke WA, Reed RA, Manas D, Forsyth RJ, Kenney RR, Cook J, Holahan M.
Compatibility of tirofiban HCl with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride during simulated Y-site administration.
J Clin Pharm Ther 1999 ; 24: 125-132.
1490 Czasopismo Halpern NA, Colucci RD, Alicea M, Greenstein R.
The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1512 Laboratorium Tirofiban (Aggrastat®) - Summary of Product Characteristics
Beacon Pharmaceuticals Ltd 2015
1625 Czasopismo Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1712 Czasopismo Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233.
1713 Czasopismo Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315.
1715 Czasopismo Storms ML, Stewart JT, Warren FW.
Stability of lidocaine hydrochloride injection at ambient temperature and 4°C in polypropylene syringes.
Int J Pharm Compound 2002 ; 6: 388-390.
1721 Czasopismo Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72.
1801 Czasopismo Feddema S, Rusho WJ, Tyler LS, Barker B.
Physical compatibility of vasopressin with medications commonly used in cardiac arrest.
Am J Health-Syst Pharm 2003 ; 60: 1271-1272.
1803 Czasopismo Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925 Czasopismo Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1937 Czasopismo Lai JJ, Brodeur SK.
Physical and chemical stability of daptomycin with nine medications.
Ann Pharmacotherapy 2004 ; 38: 1612-1616.
1963 Czasopismo Honisko ME, Fink JM, Militello MA, Mauro VF, Alexander KS.
Compatibility of argatroban with selected cardiovascular agents.
Am J Health-Syst Pharm 2004 ; 61: 2415-2418.
2053 Czasopismo Masaki Y, Tanaka M, Nishikawa T.
Physicochemical compatibility of propofol-lidocaine mixture.
Anesth Analg 2003 ; 97: 1646-1651.
2090 Czasopismo Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196.
2108 Czasopismo Trusley C, Kupiec TC, Trissel LA.
Compatibility of micafungin injection with other drugs during simulated Y-site co-administration.
Int J Pharm Compound 2006 ; 10: 230-232.
2269 Czasopismo Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2271 Laboratorium Daptomycine (Cubicin®) Résumé des caractéristiques du produits
Novartis 2006
2279 Czasopismo Kupiec T, Trusley C, Ben M, Trissel LA.
Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 18: 1735-1759.
2346 Czasopismo Newland A.M, Mauro V.F, Alexander K.S.
Physical compatibility of metoprolol tartrate injection with selected cardiovascular agents
Am J Health-Syst Pharm 2009 ; 66: 986-987.
2878 Czasopismo Pascuet E, Donnelly RF, Garceau D, Vaillancourt R.
Buffered Lidocaine Hydrochloride Solution With and Without Epinephrine: Stability in Polypropylene Syringes.
Can J Hosp Pharm 2009 ; 62, 5: 375-380.
3012 Czasopismo Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220.
3184 Laboratorium
Hyaluronidase (Hyalase®) - Summary of Product characteristics.
CP Pharmaceuticals 2005
3249 Czasopismo Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3263 Czasopismo Donnelly R.F.
Stability of buffered lidocaine in glass vials.
Can J Hosp Pharm 2011 ; 64, 4: 289-290.
3332 Laboratorium Tigecycline (Tigacyl®) - Summary of Product characteristics
Pfizer 2012
3408 Czasopismo Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21.
3420 Czasopismo El Kateb N, Chaussard M, Bellenger P, Petit A, Faure P.
Stability of an extemporaneously prepared bleomycin-lidocaine-epinephrine intradermal admixture used in dermatology
J Oncol Pharm Practice 2014 ; 21, 3: 178-187.
3502 Laboratorium Propofol (Diprivan®) - Summary of Products Characteristics
Astra Zeneca 2012
3546 Laboratorium Cefamandole Flavelab - Résumé des caractéristiques du produit
Panpharma SA 2007
3687 Laboratorium Cefuroxime sodium - Summary of Product Characteristics
Stravencon 2013
3766 Czasopismo Forrest J.M, Hildgen P.
Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels
Pharmactuel 2014 ; 47, 3 : 161-165.
3824 Czasopismo Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98
3827 Plakat Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3828 Plakat Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 Plakat So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3932 Laboratorium Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit
Serb Laboratoire 2015
3934 Laboratorium Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit
GlaxoSmithKline Laboratoire 2016
3964 Czasopismo Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33.
4055 Czasopismo Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145 Czasopismo Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319 Czasopismo Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4350 Czasopismo Beiler B, Barraud D, Vigneron J, Demor? B.
Physicochemical stability of an admixture of lidocaine and ketamine in polypropylene syringe used in opioid-free anaesthesia.
EJHP 2019 ;0:1-5
4433 Czasopismo Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.
Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications
Clin Ther 2020 ; 42, 3: 475-485.
4457 Czasopismo Houlihan, S, Decarie, D, Benes, C, Cleve, R, Vidler M, Magee L.A, Ensom M.H.H, vonDadelszen P.
Magnocaine: Physical Compatibility and Chemical Stability of Magnesium Sulphate and Lidocaine Hydrochloride in Prefilled Syringes.
J Obstet Gynaecol Can 2016 ;38,10:936e944.
4528 Czasopismo Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4603 Czasopismo Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.
4650 Laboratorium Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021
4742 Czasopismo Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255.

  Mentions Légales